8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 10, 2026·SEC
Protara Therapeutics, Inc.(TARA)Earnings, Financials & Key Ratios
TARA•NASDAQ
Price updated Jun 19, 2026
AboutProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$64M-31.5%
- Net Income-$57M-28.8%
- EPS (Diluted)-1.34+38.2%
- ROE-31.6%+16.6%
TARA Key Insights
Protara Therapeutics, Inc. (TARA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Profits declining 11.1% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TARA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TARA Price & Volume
Protara Therapeutics, Inc. (TARA) stock price & volume — 10-year historical chart
Loading chart...
TARA Growth Metrics
Protara Therapeutics, Inc. (TARA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-39.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.12%
Return on Capital
10 Years-57.9%
5 Years-39.63%
3 Years-41.25%
Last Year-34.98%
TARA Recent Earnings
Protara Therapeutics, Inc. (TARA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.31+13.9%
$0.36
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.37-15.6%
$0.32
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.31+20.5%
$0.39
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.35+18.6%
$0.43
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.31vs $0.36+13.9% | — |
| Q2 2026 | Mar 10, 2026 | $0.37vs $0.32-15.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.31vs $0.39+20.5% | — |
| Q3 2025 | Aug 11, 2025 | $0.35vs $0.43+18.6% | — |
Based on last 12 quarters of dataView full earnings history →
TARA Peer Comparison
Protara Therapeutics, Inc. (TARA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 URGN | 1.64B | 33.57 | -10.52 | 21.45% | -94.83% | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare TARA vs Peers
Protara Therapeutics, Inc. (TARA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TARA Income Statement
Protara Therapeutics, Inc. (TARA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 148K | 115K | 16K | 196K | 0 | 0 | 341K | 0 | 362K | 90K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -148K▲ 0% | -115K▲ 22.3% | -16K▲ 86.1% | -196K▼ 1125.0% | 0▲ 100.0% | 0▲ 0% | -341K▲ 0% | 0▲ 100.0% | -362K▲ 0% | -90K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -20.33% | 22.3% | 86.09% | -1125% | 100% | - | - | 100% | - | - |
Operating Expenses | 30.21M | 26.08M | 15.25M | 34.25M | 47.49M | 67.06M | 43.27M | 49.15M | 64.19M | 69.96M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 8.53M | 10.57M | 8.82M | 22.36M | 26.4M | 20.74M | 18.62M | 17.45M | 21.92M | 23.01M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 21.69M | 15.51M | 6.44M | 11.88M | 21.09M | 16.81M | 24.79M | 31.7M | 42.63M | 46.96M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 207K | 0 | 0 | 0 | 29.52M | -137K | 0 | -362K | 0 |
Operating Income | -30.36M▲ 0% | -26.08M▲ 14.1% | -15.25M▲ 41.5% | -34.44M▼ 125.8% | -47.49M▼ 37.9% | -67.06M▼ 41.2% | -43.61M▲ 35.0% | -49.15M▼ 12.7% | -64.55M▼ 31.3% | -70.05M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -5.77% | 14.1% | 41.51% | -125.8% | -37.87% | -41.22% | 34.97% | -12.7% | -31.32% | - |
EBITDA | -30.21M | -25.96M | -15.24M | -34.25M | -47.37M | -66.81M | -43.27M | -48.82M | -64.19M | -69.69M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -5.71% | 14.06% | 41.31% | -124.75% | -38.32% | -41.04% | 35.24% | -12.83% | -31.47% | -36.38% |
D&A (Non-Cash Add-back) | 148K | 115K | 16K | 196K | 117K | 248K | 341K | 332K | 362K | 369K |
EBIT | -29.96M | -20.73M | -7.83M | -33.98M | -45.52M | -64.81M | -43.61M | -49.15M | -64.55M | -70.05M |
Net Interest Income | 0 | 0 | 0 | 432K | -1.5M | -27K | 2.73M | 4.13M | 6.33M | 6.45M |
Interest Income | 0 | 0 | 0 | 466K | 237K | 1.11M | 2.73M | 4.13M | 6.33M | 6.45M |
Interest Expense | 259K | 0 | 0 | 34K | 1.74M | 1.14M | 0 | 0 | 0 | 0 |
Other Income/Expense | 398K | 643K | 0 | 466K | 237K | 1.11M | 3.19M | 4.56M | 7.11M | 6.75M |
Pretax Income | -29.96M▲ 0% | -25.44M▲ 15.1% | -14.99M▲ 41.1% | -33.98M▼ 126.6% | -47.25M▼ 39.1% | -65.95M▼ 39.6% | -40.42M▲ 38.7% | -44.6M▼ 10.3% | -57.44M▼ 28.8% | -63.31M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 5.35M | -262K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -21.04% | 1.75% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -29.96M▲ 0% | -25.44M▲ 15.1% | -14.99M▲ 41.1% | -33.98M▼ 126.6% | -47.25M▼ 39.1% | -65.95M▼ 39.6% | -40.42M▲ 38.7% | -44.6M▼ 10.3% | -57.44M▼ 28.8% | -63.31M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -5.04% | 15.11% | 41.06% | -126.64% | -39.07% | -39.57% | 38.71% | -10.33% | -28.8% | -39.4% |
Net Income (Continuing) | -29.96M | -20.73M | -7.83M | -33.98M | -47.25M | -65.95M | -40.42M | -44.6M | -57.44M | -63.31M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -69.38▲ 0% | -9.93▲ 85.7% | -3.63▲ 63.4% | -4.70▼ 29.5% | -4.20▲ 10.6% | -5.86▼ 39.5% | -3.57▲ 39.1% | -2.17▲ 39.2% | -1.34▲ 38.2% | -1.48▲ 0% |
EPS Growth % | -0.7% | 85.69% | 63.44% | -29.48% | 10.64% | -39.52% | 39.08% | 39.22% | 38.25% | 15.12% |
EPS (Basic) | -69.38 | -9.93 | -3.63 | -4.70 | -4.20 | -5.86 | -3.57 | -2.17 | -1.34 | - |
Diluted Shares Outstanding | 431.86K | 2.56M | 4.06M | 7.23M | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M | 42.84M |
Basic Shares Outstanding | 431.86K | 2.56M | 4.06M | 7.23M | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M | 42.84M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TARA Balance Sheet
Protara Therapeutics, Inc. (TARA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 43.48M | 23.24M | 6.97M | 169.44M | 93.11M | 86.15M | 68.7M | 172.16M | 159.5M | 140M |
Cash & Short-Term Investments | 42.14M | 21.87M | 6.18M | 168.6M | 91.23M | 84.37M | 65.58M | 170.29M | 155.55M | 135.79M |
Cash Only | 21.17M | 19.37M | 6.18M | 168.6M | 35.72M | 24.13M | 39.59M | 162.8M | 49.66M | 14.74M |
Short-Term Investments | 20.97M | 2.5M | 0 | 0 | 55.51M | 60.24M | 25.99M | 7.49M | 105.9M | 121.05M |
Accounts Receivable | 0 | 0 | 0 | 0 | 634K | 486K | 242K | 0 | 1.26M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 1.16M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 22.31M | 0 | 716K | 102K | 34K | -1.04M | 37K | 2K | 2.69M | 4.21M |
Total Non-Current Assets | 499K | 285K | 581K | 33.72M | 79.48M | 27.14M | 10.25M | 9.3M | 49.96M | 51.93M |
Property, Plant & Equipment | 259K | 263K | 459K | 2.3M | 8.89M | 7.87M | 6.56M | 5.28M | 3.93M | 3.56M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 29.52M | 29.52M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 84K | 2.66M | 3.25M | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 39.47M | 17.89M | 0 | 0 | 0 | 24.35M |
Other Non-Current Assets | 240K | 22K | 122K | 1.91M | 1.61M | 1.3M | 1.03M | 772K | 46.03M | 48.37M |
Total Assets | 43.98M▲ 0% | 23.52M▼ 46.5% | 6.97M▼ 70.3% | 203.16M▲ 2812.6% | 172.6M▼ 15.0% | 113.29M▼ 34.4% | 78.95M▼ 30.3% | 181.45M▲ 129.8% | 209.47M▲ 15.4% | 191.92M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 1.05% | -46.52% | -70.35% | 2812.65% | -15.04% | -34.36% | -30.31% | 129.82% | 15.44% | 137.41% |
Total Current Liabilities | 9.24M | 3.08M | 583K | 2.92M | 4.3M | 5.74M | 6.15M | 10.96M | 10.94M | 8.92M |
Accounts Payable | 0 | 441K | 716K | 914K | 954K | 1.59M | 2.43M | 4.43M | 3.47M | 4.03M |
Days Payables Outstanding | - | 1.4K | 16.33K | 1.7K | - | - | 2.61K | - | 3.5K | 17.54K |
Short-Term Debt | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.24M | 1.26M |
Deferred Revenue (Current) | -28.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.89M | 0 | -137K | 1.53M | 1.8M | 2.54M | 2.11M | 2.53M | 6.23M | 3.63M |
Current Ratio | 4.71x | 7.55x | 11.96x | 58.13x | 21.66x | 15.01x | 11.17x | 15.71x | 14.58x | 15.69x |
Quick Ratio | 4.71x | 7.55x | 11.96x | 58.13x | 21.66x | 14.81x | 11.17x | 15.71x | 14.58x | 15.69x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 999K | 6.38M | 5.47M | 4.48M | 3.36M | 2.12M | 1.79M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.79M |
Capital Lease Obligations | 0 | 0 | 0 | 999K | 6.38M | 5.47M | 4.48M | 3.36M | 2.12M | 7.3M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9.24M | 3.08M | 583K | 3.91M | 10.68M | 11.21M | 10.63M | 14.32M | 13.06M | 10.71M |
Total Debt | 20K | 0 | 0 | 1.09M | 7.24M | 6.38M | 5.47M | 4.48M | 3.36M | 3.06M |
Net Debt | -21.15M | -19.37M | -6.18M | -167.51M | -28.48M | -17.74M | -34.12M | -158.31M | -46.3M | -11.68M |
Debt / Equity | 0.00x | - | - | 0.01x | 0.04x | 0.06x | 0.08x | 0.03x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.17x |
Interest Coverage | -115.69x | - | - | -999.35x | -26.20x | -57.01x | - | - | - | - |
Total Equity | 34.74M▲ 0% | 20.44M▼ 41.2% | 6.39M▼ 68.7% | 199.24M▲ 3017.1% | 161.91M▼ 18.7% | 102.08M▼ 37.0% | 68.32M▼ 33.1% | 167.13M▲ 144.6% | 196.41M▲ 17.5% | 181.21M▲ 0% |
Equity Growth % | -9.63% | -41.15% | -68.73% | 3017.07% | -18.74% | -36.95% | -33.07% | 144.63% | 17.52% | 150.5% |
Book Value per Share | 80.44 | 7.98 | 1.57 | 27.54 | 14.41 | 9.07 | 6.03 | 8.12 | 4.59 | 4.23 |
Total Shareholders' Equity | 34.74M | 20.44M | 6.39M | 199.24M | 161.91M | 102.08M | 68.32M | 167.13M | 196.41M | 181.21M |
Common Stock | 18K | 19K | 3K | 11K | 11K | 11K | 11K | 35K | 54K | 55K |
Retained Earnings | -189.74M | -210.47M | -225.46M | -46.76M | -94.01M | -159.96M | -200.38M | -244.98M | -302.42M | -320.2M |
Treasury Stock | 202.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -14K | 5K | 3K | 0 | -211K | -688K | -31K | 2K | 90K | -364K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TARA Cash Flow Statement
Protara Therapeutics, Inc. (TARA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -22.35M | -23.23M | -15.65M | -23.41M | -34.5M | -26.46M | -37.56M | -35.81M | -56.37M | -62.99M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 5.64% | -3.94% | 32.66% | -49.6% | -47.4% | 23.32% | -41.95% | 4.66% | -57.41% | -234.16% |
Net Income | -29.96M | -20.73M | -14.99M | -33.98M | -47.25M | -65.95M | -40.42M | -44.6M | -57.44M | -63.31M |
Depreciation & Amortization | 148K | 115K | 279K | 196K | 117K | 248K | 341K | 332K | 362K | 369K |
Stock-Based Compensation | 926 | 3.43M | 943K | 9.75M | 10.36M | 6.69M | 6.09M | 4.13M | 3.83M | 4.36M |
Deferred Taxes | 0 | 0 | 0 | -9.94M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.39M | -76K | -4K | 9.94M | 1.74M | 32.02M | 569K | 324K | -173K | -177K |
Working Capital Changes | 4.41M | -5.97M | -1.87M | 629K | 534K | 539K | -4.14M | 4.01M | -2.94M | -4.24M |
Change in Receivables | -46K | 49K | 17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | -41.79M | 0 | -17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 4.16M | -6.16M | -2.5M | 198K | 40K | 631K | 848K | 1.38M | -873K | 1.72M |
Cash from Investing | -16.1M | 18.43M | 2.48M | 2.83M | -98.19M | 14.95M | 53.11M | 19.16M | -139.49M | -95.86M |
Capital Expenditures | -35K | -119K | -16K | -884K | -596K | -120K | -45K | -63K | -94K | -50K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 3.72M | 97.6K | -15.07K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -97.6K | 15.07K | 0 | 0 | 0 | 0 |
Cash from Financing | 23.05M | 2.98M | 500K | 189.4M | -228K | -90K | -91K | 139.87M | 82.72M | 82.13M |
Debt Issued (Net) | 0 | 0 | 0 | -1.67M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 1.53M | 2.85M | 500K | 179.45M | -228K | -90K | -91K | 136.01M | 82.9M | 82.4M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -228K | -90K | -91K | 0 | 0 | 0 |
Other Financing | 21.52M | 132K | 0 | 11.62M | 0 | 0 | 0 | 3.86M | -185K | -272K |
Net Change in Cash | -15.22M▲ 0% | -1.8M▲ 88.2% | -13.16M▼ 631.6% | 168.83M▲ 1382.7% | -132.92M▼ 178.7% | -11.6M▲ 91.3% | 15.46M▲ 233.3% | 123.21M▲ 697.0% | -113.14M▼ 191.8% | -76.72M▲ 0% |
Free Cash Flow | -22.39M▲ 0% | -23.35M▼ 4.3% | -15.66M▲ 32.9% | -24.29M▼ 55.1% | -35.1M▼ 44.5% | -26.58M▲ 24.3% | -37.6M▼ 41.5% | -35.87M▲ 4.6% | -56.46M▼ 57.4% | -63.05M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 6.56% | -4.31% | 32.93% | -55.1% | -44.49% | 24.28% | -41.48% | 4.6% | -57.39% | -56.64% |
FCF per Share | -51.84 | -9.12 | -3.86 | -3.36 | -3.12 | -2.36 | -3.32 | -1.74 | -1.32 | -1.47 |
FCF Conversion (FCF/Net Income) | 0.75x | 0.91x | 1.04x | 0.69x | 0.73x | 0.40x | 0.93x | 0.80x | 0.98x | 1.00x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TARA Key Ratios
Protara Therapeutics, Inc. (TARA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -81.89% | -92.19% | -111.73% | -33.05% | -26.17% | -49.96% | -47.44% | -37.88% | -31.6% | -38.7% |
Return on Invested Capital (ROIC) | -291.23% | -266.83% | -1783.4% | -161.74% | -43.13% | -46.19% | -55.19% | -171.38% | -60.92% | -37.53% |
Debt / Equity | 0.00x | - | - | 0.01x | 0.04x | 0.06x | 0.08x | 0.03x | 0.02x | 0.02x |
Interest Coverage | -115.69x | - | - | -999.35x | -26.20x | -57.01x | - | - | - | - |
FCF Conversion | 0.75x | 0.91x | 1.04x | 0.69x | 0.73x | 0.40x | 0.93x | 0.80x | 0.98x | 1.00x |
Related:TARA Dividend History·TARA Revenue History·TARA Price History·TARA P/E History·TARA Financial Ratios·TARA Institutional Holders
TARA SEC Filings & Documents
Protara Therapeutics, Inc. (TARA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TARA Frequently Asked Questions
Protara Therapeutics, Inc. (TARA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Protara Therapeutics, Inc. (TARA) grew revenue by 0.0% over the past year. Growth has been modest.
Protara Therapeutics, Inc. (TARA) reported a net loss of $63.3M for fiscal year 2025.
Dividend & Returns
Protara Therapeutics, Inc. (TARA) has a return on equity (ROE) of -31.6%. Negative ROE indicates the company is unprofitable.
Protara Therapeutics, Inc. (TARA) had negative free cash flow of $63.0M in fiscal year 2025, likely due to heavy capital investments.